Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: Results from an International Antimicrobial Surveillance Program

Journal of Clinical Microbiology

Volumn 44, Issue 7, 2006, Pages 2622-2625

  Jones, Ronald N ^a,b   Sader, Helio S ^a   Fritsche, Thomas R ^a   Hogan, Patricia A ^c   Sheehan, Daniel J ^c  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALBAVANCIN; GLYCOPEPTIDOLIPID; LIPOPEPTIDE; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ACCURACY; ALPHA HEMOLYTIC STREPTOCOCCUS; ANALYTICAL ERROR; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; ENTEROCOCCUS; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELIABILITY; STAPHYLOCOCCUS AUREUS; VALIDATION STUDY;

ANTI-BACTERIAL AGENTS; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS; STATISTICS; STREPTOCOCCUS; TEICOPLANIN; VANCOMYCIN;

STAPHYLOCOCCUS;

EID: 33746216105     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00576-06     Document Type: Article

References (21)

1. Barry, A. L., and R. N. Jones. 1987. Cross susceptibility and absence of cross resistance to cefotetan and cefoxitin. J. Clin. Microbiol. 25:1570-1571.
2. Buckwalter, M., and J. A. Dowell. 2005. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J. Clin. Pharmacol. 45:1279-1287.
3. Candiani, G., M. Abbondi, M. Borgonovi, G. Romano, and F. Parenti. 1999. In-vitro and in-vivo antibacterial activity of Bl 397, a new semi-synthetic glycopeptide antibiotic. J. Antimicrob. Chemother. 44:179-192.
4. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Document M7-A7. Clinical and Laboratory Standards Institute, Wayne, Pa.
5. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing, 16th informational supplement M100-S16. Clinical and Laboratory Standards Institute, Wayne, Pa.
6. Dorr, M. B., D. Jabes, M. Cavaleri, J. Dowell, G. Mosconi, A. Malabarba, R. J. White, and T. J. Henkel. 2005. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J. Antimicrob. Chemother. 55(Suppl. 2):ii25-ii30.
7. Gales, A. C., H. S. Sader, and R. N. Jones. 2005. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres. Clin. Microbiol. Infect. 11:95-100.
8. Jauregui, L. E., S. Babazadeh, E. Seltzer, L. Goldberg, D. Krievins, M. Frederick, D. Krause, I. Satilovs, Z. Endzinas, J. Breaux, and W. O'Riordan. 2005. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis. 41:1407-1415.
9. Jones, R. N., D. J. Biedenbach, D. M. Johnson, and M. A. Pfaller. 2001. In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent. J. Chemother. 13:244-254.
10. Jones, R. N., T. R. Fritsche, H. S. Sader, and B. P. Goldstein. 2005. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol. J. Chemother. 17:593-600.
11. Jones, R. N., and M. A. Pfaller. 2001. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: report from The SENTRY Antimicrobial Surveillance Program (1997-99). Diagn. Microbiol. Infect. Dis. 39:237-243.
12. Jones, R. N., M. G. Stilwell, H. S. Sader, T. R. Fritsche, and B. P. Goldstein. 2006. Spectrum and potency of dalbavancin tested against 3,322 Gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn. Microbiol. Infect. Dis. 54:149-153.
13. Jones, R. N., J. M. Streit, and T. R. Fritsche. 2004. Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide. Int. J. Antimicrob. Agents 23:197-199.
14. Jones, R. N., and G. E. Zurenko. 1993. Prediction of bacterial susceptibility to cefpodoxime by using the ceftriaxone minimum inhibitory concentration result. Diagn. Microbiol. Infect. Dis. 17:313-316.
15. Leighton, A., A. B. Gottlieb, M. B. Dorr, D. Jabes, G. Mosconi, C. VanSaders, E. J. Mroszczak, K. C. Campbell, and E. Kelly. 2004. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob. Agents Chemother. 48:940-945.
16. Lin, G., K. Credito, L. M. Ednie, and P. C. Appelbaum. 2005. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob. Agents Chemother. 49:770-772.
17. Malabarba, A., and B. P. Goldstein. 2005. Origin, structure, and activity in vitro and in vivo of dalbavancin. J. Antimicrob. Chemother. 55(Suppl. 2): ii15-ii20.
18. National Committee for Clinical Laboratory Standards. 2001. Approved guideline M23-A2: development of in vitro susceptibility testing criteria and quality controls parameters, 2nd ed. National Committee for Clinical Laboratory Standards, Wayne, Pa.
19. Raad, I., R. Darouiche, J. Vazquez, A. Lentnek, R. Hachem, H. Hanna, B. Goldstein, T. Henkel, and E. Seltzer. 2005. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin. Infect. Dis. 40:374-380.
20. Seltzer, E., M. B. Dorr, B. P. Goldstein, M. Perry, J. A. Dowell, and T. Henkel. 2003. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin. Infect. Dis. 37:1298-1303.
21. Streit, J. M., T. R. Fritsche, H. S. Sader, and R. N. Jones. 2004. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn. Microbiol. Infect. Dis. 48:137-143.